These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 16006752)

  • 1. Immunochemotherapy with rituximab, vincristine and 5-day cyclophosphamide for heavily pretreated follicular lymphoma.
    Lazzarino M; Arcaini L; Orlandi E; Iacona I; Bernasconi P; Calatroni S; Varettoni M; Isa L; Brusamolino E; Bonfichi M; Passamonti F; Burcheri S; Pascutto C; Regazzi M
    Oncology; 2005; 68(2-3):146-53. PubMed ID: 16006752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
    Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
    Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma.
    Zinzani PL; Pulsoni A; Perrotti A; Soverini S; Zaja F; De Renzo A; Storti S; Lauta VM; Guardigni L; Gentilini P; Tucci A; Molinari AL; Gobbi M; Falini B; Fattori PP; Ciccone F; Alinari L; Martelli M; Pileri S; Tura S; Baccarani M
    J Clin Oncol; 2004 Jul; 22(13):2654-61. PubMed ID: 15159414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up.
    Czuczman MS; Weaver R; Alkuzweny B; Berlfein J; Grillo-López AJ
    J Clin Oncol; 2004 Dec; 22(23):4711-6. PubMed ID: 15483015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab plus short-duration chemotherapy as first-line treatment for follicular non-Hodgkin's lymphoma: a phase II trial of the minnie pearl cancer research network.
    Hainsworth JD; Litchy S; Morrissey LH; Andrews MB; Grimaldi M; McCarty M; Greco FA
    J Clin Oncol; 2005 Mar; 23(7):1500-6. PubMed ID: 15632411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone.
    Taskinen M; Karjalainen-Lindsberg ML; Nyman H; Eerola LM; Leppä S
    Clin Cancer Res; 2007 Oct; 13(19):5784-9. PubMed ID: 17908969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial of sequential therapy with fludarabine followed by cyclophosphamide, mitoxantrone, vincristine, and prednisone for low-grade follicular lymphomas.
    Rohatgi N; LaRocca RV; Bard V; Sethuraman G; Foon KA
    Am J Hematol; 2002 Jul; 70(3):181-5. PubMed ID: 12111762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma.
    Tam CS; Wolf M; Prince HM; Januszewicz EH; Westerman D; Lin KI; Carney D; Seymour JF
    Cancer; 2006 Jun; 106(11):2412-20. PubMed ID: 16649223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined treatment with anti-CD20 (rituximab) and CHOP in relapsed advanced-stage follicular lymphomas.
    Domingo-Domènech E; González-Barca E; Estany C; Sureda A; Besalduch J; Fernández de Sevilla A
    Haematologica; 2002 Nov; 87(11):1229-30. PubMed ID: 12414357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of the combination of rituximab, fludarabine, and mitoxantrone for rituximab-naive, recurrent/refractory follicular non-Hodgkin lymphoma with high tumor burden: a multicenter phase 2 trial by the Groupe d'Etude des Lymphomes de l'Adulte (GELA) and Groupe Ouest Est des Leucémies et Autres Maladies du Sang (GOELAMS).
    Morschhauser F; Mounier N; Sebban C; Brice P; Solal-Celigny P; Tilly H; Feugier P; Fermé C; Copin MC; Lamy T
    Cancer; 2010 Sep; 116(18):4299-308. PubMed ID: 20549824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical analysis of rituximab combined with chemotherapy in treating aggressive B-cell non-Hodgkin's lymphoma].
    Zhang HY; Lin TY; Jiang WQ; Zhang L; Huang HQ; Xia ZJ; Sun XF; He YJ; Guan ZZ
    Ai Zheng; 2004 Dec; 23(12):1681-6. PubMed ID: 15601560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma.
    Shah GD; Yahalom J; Correa DD; Lai RK; Raizer JJ; Schiff D; LaRocca R; Grant B; DeAngelis LM; Abrey LE
    J Clin Oncol; 2007 Oct; 25(30):4730-5. PubMed ID: 17947720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anthracycline-fludarabine-containing regimens with or without rituximab in the treatment of patients with advanced follicular lymphoma.
    Luminari S; Marcheselli L; Sacchi S; Pozzi S; Bari A; Ilariucci F; Stelitano C; Angrilli F; Lazzaro A; Baldini L
    Cancer; 2009 May; 115(9):1906-13. PubMed ID: 19248044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma.
    Sacchi S; Pozzi S; Marcheselli R; Federico M; Tucci A; Merli F; Orsucci L; Liberati M; Vallisa D; Brugiatelli M;
    Cancer; 2007 Jul; 110(1):121-8. PubMed ID: 17503433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accelerated R-COP: a pilot study for the treatment of advanced low grade lymphomas that has a high complete response rate.
    Levitt MJ; Gharibo M; Strair R; Schaar D; Rubin A; Bertino JR
    J Chemother; 2009 Aug; 21(4):434-8. PubMed ID: 19622463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma.
    Czuczman MS; Koryzna A; Mohr A; Stewart C; Donohue K; Blumenson L; Bernstein ZP; McCarthy P; Alam A; Hernandez-Ilizaliturri F; Skipper M; Brown K; Chanan-Khan A; Klippenstein D; Loud P; Rock MK; Benyunes M; Grillo-Lopez A; Bernstein SH
    J Clin Oncol; 2005 Feb; 23(4):694-704. PubMed ID: 15681517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liposome-encapsulated doxorubicin in combination with cyclophosphamide, vincristine, prednisone and rituximab in patients with lymphoma and concurrent cardiac diseases or pre-treated with anthracyclines.
    Rigacci L; Mappa S; Nassi L; Alterini R; Carrai V; Bernardi F; Bosi A
    Hematol Oncol; 2007 Dec; 25(4):198-203. PubMed ID: 17654614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bortezomib ADDED to R-CVP is safe and effective for previously untreated advanced-stage follicular lymphoma: a phase II study by the National Cancer Institute of Canada Clinical Trials Group.
    Sehn LH; MacDonald D; Rubin S; Cantin G; Rubinger M; Lemieux B; Basi S; Imrie K; Gascoyne RD; Sussman J; Chen BE; Djurfeldt M; Shepherd L; Couban S; Crump M
    J Clin Oncol; 2011 Sep; 29(25):3396-401. PubMed ID: 21810681
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of bortezomib in combination with rituximab, cyclophosphamide and prednisone with or without doxorubicin followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma.
    Craig M; Hanna WT; Cabanillas F; Chen CS; Esseltine DL; Neuwirth R; O'Connor OA
    Br J Haematol; 2014 Sep; 166(6):920-8. PubMed ID: 25039282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.